Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiol TherapeuticsSTU:CT9 +5.03%40 Buyback Yield % is -8.59 as of Jul. 14, 2026. GuruFocus rates STU:CT9 with a GF Score™ of 40/100. The stock has 3 warning signs investors should review. Among 290 Drug Manufacturers companies, Cardiol Therapeutics ranks worse than 76.21% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Cardiol Therapeutics Buyback Yield % Related Terms
Cardiol Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Cardiol Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiol Therapeutics Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Cardiol Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiol Therapeutics (STU:CT9) has a Buyback Yield % of -8.59 as of Jul. 14, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cardiol Therapeutics and its competitors. According to the industry distribution chart, Cardiol Therapeutics ranks #221 out of 290 companies in the Drug Manufacturers industry, placing it in the top 76.2%.
Is Cardiol Therapeutics' Buyback Yield % too high?
Cardiol Therapeutics' current Buyback Yield % is -8.59. Based on the distribution chart, Cardiol Therapeutics ranks #221 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cardiol Therapeutics has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cardiol Therapeutics ranks #221 out of 290 companies for Buyback Yield %. This places Cardiol Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cardiol Therapeutics and its competitors. Cardiol Therapeutics's current Buyback Yield % is -8.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (STU:CT9) has a current Buyback Yield % of -8.59. The current Buyback Yield % is -8.59. Cardiol Therapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Cardiol Therapeutics (STU:CT9), the current Buyback Yield % is -8.59 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
40GF Score
Get the complete analysis for STU:CT9
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CT9 has been successfully added to your 
